Ν. ΧΡΥΣΟΧΟΪΛΗΣ ΧΡΗΜΑΤΙΣΤΗΡΙΑΚΗ

ΑΝΩΝΥΜΟΣ ΕΤΑΙΡΕΙΑ ΠΑΡΟΧΗΣ ΕΠΕΝΑΥΤΙΚΩΝ ΥΠΗΡΕΣΙΩΝ Μέλος του Χρηματιστηρίου Αξιών Αθηνών Μέλος του Χρηματιστηρίου Παραγώγων Αθηνών

6,56

12/15

278.760.000

28.522.915

10%

0.21

0.54

0.16

13.66

260.782.365

34.770.982

32.137.122

12/16E

310.173.400

36.231.877

203,116,108

170 978 986

12%

0.21

0.62

0.18

11,00

12/17E

318.510.116

37.859.237

0.20

Μέλος του Δικτύου XNet Τμήμα Μελετών και Αναλύσεων

Share Price:

Price High 52week

Price Low 52week

Long Term Debt

Key Financials

EBITDA

P/E

EBITDA margin

Total Debt/Equity

Dividend/Share

Enterprise Value

Shareholders value

Market capitalisation

Current num. of shares

Closing Price as 16/03/16



N. CHRYSSOCHOIDIS STOCK BROKERAGE

INVESTMENT SERVICES S.A. Member of the Athens Stock Exchange
Member of the Athens Derivatives Exchange Member of the XNet Network

Equity Research Department

SARANTIS

SECTOR: Personal & Household goods-Personal products

ACTIVITY: Formulation and supply of cosmetics products.

Outlook:

Sarantis Group FY15 Revenues exceeded our expectations (+13% vs +8%). The growth of Group's Revenues reflects both the gain in market share in the countries which the group operates and the positive contribution of the latest acquisitions of Noxzema and Ava brands.

In terms of operating and gross profit margins, the group expects a slight improvement due to the positive contribution of own products to the overall sales mix.

For FY16, we perceive higher total sales growth (+10%) in line with company's guidance due to the evidenced organic increase in domestic and foreign retail sales and the contribution of the latest acquisition (Polipack) to total revenues.

We factor in our model increased group revenues for the 2016-2019 period in order to reflect Polipack's contribution in total sales (c.15mn years per annum) and an increased growth rate in revenues for the main Geographical areas which the group operates . Additionally, we keep the operating margins stable and adjust our expectations for 12% CAPEX as the guidance indicates for the same period 0.21

11,00 These adjustmens lead us to re-estimate Group's cumulative revenues and Free cash flows for the 2016-2019 period to c.1.3bn Euros vs c.1.1bn Euros and c.50mn Euros vs c.45 mn Euros respectivelly.

> We reconfirm Sarantis's Fair Estimated Price at 5.5 Euros/Share, due to management's ability and expertise, solid balance sheet and satisfactory track record regarding annual guidance which are key factors in our valuation

We still believe that Sarantis is an interesting long term business case, Fair Price could amount to 6,00 Euros/Share, yet a bit pricey one at current levels.

Strengths:

We expect an increase of c.10% in total sales for the full year of 2016 due to the contribution from the foreign countries in line with the management's guidance.

Opportunities:

The rapid growth of the Balkan economies which Sarantis group operates is possible to increase profitability and operating margins.

Threats:

Unstable domestic economic environment.

While we believe that the current share price is higher than our estimated fair value we should not ignore the fact that the group succesfully operates in sales and production of cosmetics. Sarantis's management capital structure and operations have already proved resilient to the consequences of the recession. Moreover a possible recovery and stability in the economies which the group operates could spectacularly improve its operating and profitability margins.

Date 1	7/03/	16
--------	-------	----

FAIR ESTIMATED PRICE	5,5
∆% from Current Price	-27%
Investment Thesis	OV

SARANTIS Summary tables

Income Statement	2015	2016E	2017E 2018E		2019E
Sales	278.760.000,00	310.173.400,00	318.510.116,00 324.880.318,32		331.377.924,69
Cost of goods	146.262.092,82	161.290.168,00	165.625.260,32	167.313.363,93	170.659.631,21
Gross Profit	132.497.907,18	148.883.232,00	152.884.855,68	157.566.954,39	160.718.293,47
Other Income	7.743.734,96	4.761.798,90			4.761.798,90
Administrative Costs	14.115.376,57	14.821.145,40			15.728.318,07
Sales Costs	101.325.722,75	106.392.008,89	108.519.849,07 113.945.841,52		119.643.133,59
EBIT	24.800.542,82	32.431.876,61	34.009.237,21	32.962.992,09	30.108.640,71
Impairment Loss					
Interest Income/Expens	1.889.528,66	1.900.000,00	1.900.000,00	1.900.000,00	1.900.000,00
EBT	22.911.014,16	30.531.876,61	32.109.237,21	31.062.992,09	28.208.640,71
Tax	4.124.528,19	8.854.244,22	9.311.678,79 9.008.267,71		8.180.505,81
Deffered Tax					
Net Income	18.786.485,97	21.677.632,40	22.797.558,42	22.054.724,39	20.028.134,91
EBITDA	28.522.914,95	36.231.876,61	37.859.237,21 36.862.993		34.108.640,71
D&A	3.722.372,13	3.800.000,00	3.850.000,00 3.900.000,00		4.000.000,00

Cash flow estimations (E)	2016E	2017E	2018E
EBIT	32.431.876,61	34.009.237,21	32.962.992,09
Taxation	29%	29%	29%
NOPAT	23.026.632,40	24.146.558,42	23.403.724,39
Depreciation	3.800.000,00	3.850.000,00	3.900.000,00
IWC	5.764.775,80	2.417.647,64	1.847.358,67
Capital Exp.	3.500.000,00	3.500.000,00	3.500.000,00
NCF	17.561.856,60	22.078.910,78	21.956.365,71
Growth/Margins/Metrics(E)	12/15	12/16E	12/17E
Sales Growth	15%	4%	4,00%
EBITDA growth Y-Y	11%	27%	4%
Net Profit/Loss growth	9,53%	15,39%	5,17%
RATIOS	12/15	12/16E	12/17E
Debt/Equity	0,21	0,21	0,21
Capex/EBITDA	40%	10%	9%
ROE	11%	13%	15%
WACC	12,00%	12,00%	12,00%
VALUATION	12/15	12/16E	12/17E
Book Value	4,78	4,78	4,78
P/BV	1,61	1,15	1,15
P/E	13,68	11,00	11,00

	Σημειώσεις/Note	NG.		Oğnyác	: Συστάσεων/Ratings	
P: Τρέγουσα Τιμή		Market Price	control processing and the control of the control o			
	MCAP:	Κεφαλαιοποίηση	Capitalization	$\mathbf{U}\mathbf{V}$	Χαμηλή Αποτίμηση/ Χαμηλός Κίνδυνος	Underpriced/ Small Risk
	EPS:	Καθαρά Κέρδη Ανά Μετοχή	Earnings per Share			Stock Price < 20% of Fair
				UV1	Χαμηλή Αποτίμηση/ Κίνδυνος	Underpriced/ Risk
						Stock Price < 10% of Fair
	P/E:	Λόγος Τιμής προς Κέρδη	Price/Earnings Ratio	FV	Σωστή Αποτίμηση/ Χαμηλός Κίνδυνος	Fairly Priced/ Small Risk
						10% <stock price<10%<="" td=""></stock>
	P/S:	Λόγος Τιμής προς Πωλήσεις	Price/Sales Ratio	OV1	Σωστή Αποτίμηση/ Κίνδυνος	Fairly Priced/ Risk
						Stock Price >10% of Fair
	D/A:	Συνολικός Δανεισμός προς Παθητικό	Total Debt/Assets Ratio	ov	Υπερτιμημένη Μετοχή	Overvalued
						Stock Price >20% of Fair
	DY:	Απόδοση Μερίσματος	Dividend Yield			
	ROE:	Απόδοση Ιδίων Κεφαλαίων	Return on Equity			
	FV:	Τιμή Σωστής Αποτίμησης	Fair Value Price			

Ρήτρα Περιορισμού Ευθύνης:

πρόταση για αγορά ή πώληση μετοχών ή άλλων κινήτών αξιών. Οι επενδύσεις που αναφέρονται ενδέχεται να μην είναι οι ενδεδειγμένες για ορισμένους επενδυτές.

Disclaimer:

This report has been issued by N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A., a member of the Athens Stock Exchange, and may not be reproduced in any manner or provided to any other persons. Each person that receives a copy by acceptance thereof represents and agrees that it will not distribute or provide it to any other person. The information contained herein has been obtained from sources believed to be reliable but has not been verified by N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A. The opinions expressed herein may not necessarily coincide with those of any member of N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A. No representation or warranty (express or implied) is made as to the accuracy, completeness, correctness, timeliness or fairness of the information or opinions herein, all of which are subject to change without notice. No responsibility of liability of liability of liability whatsoever or howsoever arising is accepted in relation to the contents hereof by N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A. or any of its directors, officers or employees. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell securities mentioned herein, N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A. The opinions expressed herein may not necessarily coincide with those of any member of the normation of an offer to buy or sell or a solicitation of an offer to buy or sell securities mentioned herein, N. CHRYSSOCHOIDIS STOCK BROKERAGE I.S.S.A. or any of its directors, officers or employees. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell securities mentioned herein, N. CHRYSSOCHOIDIS STOCK BROKERAGE L.S.S.A. may effect transactions in or perform or seek to perform brokerage services for companies covered. The investments discussed in this report may be unsuitable for investors, depending on their specific investment objectives and financial position.